Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0000950170-24-002278 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-01-04 | 2024-01-03+ | DYN | McNeill Jonathan | Chief Business Off | M - OptEx | $0.73 | +20.0K | 161.6K | +14% | +$14.6K |
| DMT | 2024-01-04 | 2024-01-02+ | DYN | McNeill Jonathan | Chief Business Off | S - Sale+OE | $16.59 | -31.9K | 143.6K | -18% | -$529.2K |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | McNeill Jonathan | Chief Business Off | M - OptEx | $0.00 | -20.0K | 48.5K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-04 | M | A | 2,009 | $0.73 | 145,627 | D | — | — | (F3) Includes 143,067 unvested RSUs. |
| 2 | Common | Common Stock | 2024-01-04 | S | D | 2,009 | $18.04 | 143,618 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.07, inclusive. (F3) Includes 143,067 unvested RSUs. |
| 3 | Common | Common Stock | 2024-01-03 | S | D | 10,300 | $19.03 | 143,618 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. (F3) Includes 143,067 unvested RSUs. |
| 4 | Common | Common Stock | 2024-01-03 | M | A | 17,991 | $0.73 | 161,609 | D | — | — | (F3) Includes 143,067 unvested RSUs. |
| 5 | Common | Common Stock | 2024-01-03 | S | D | 7,691 | $18.34 | 153,918 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive. (F3) Includes 143,067 unvested RSUs. |
| 6 | Common | Common Stock | 2024-01-02 | S | D | 11,900 | $13.10 | 143,618 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.76 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. (F3) Includes 143,067 unvested RSUs. |
| 7 | Derivative | Stock option (right to buy) | 2024-01-03 | M | D | 17,991 | $0.00 | 50,537 | D | $0.73 · — to 2029-02-25 | 17,991 Common Stock | (F7) The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. |
| 8 | Derivative | Stock option (right to buy) | 2024-01-04 | M | D | 2,009 | $0.00 | 48,528 | D | $0.73 · — to 2029-02-25 | 2,009 Common Stock | (F7) The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. |